|  |  |
| --- | --- |
| **Committee:** | Southern Health and Disability Ethics Committee |
| **Meeting date:** | 10 July 2018 |
| **Meeting venue:** | Sudima Hotel, Christchurch Airport, 550 Memorial Drive, Christchurch |

|  |  |
| --- | --- |
| **Time** | **Item of business** |
| 11:30am | Welcome |
| 11:35am | Confirmation of minutes of meeting of 12 June 2018 |
| 12:00pm | New applications (see over for details) |
|  | i 18/STH/129  ii 18/STH/132  iii 18/STH/134  iv 18/STH/136  v 18/STH/137  vi 18/STH/138  vii 18/STH/139  viii 18/STH/140  ix 18/STH/141  x 18/STH/142 |
| 4:10pm | Substantial amendments (see over for details) |
|  | i 17/STH/112/AM03 |
| 4:35pm | Review of approved studies (see over for details) |
| 4:45pm | General business:   * Noting section of agenda |
| 5:00pm | Meeting ends |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Member Name** | **Member Category** | **Appointed** | **Term Expires** | **Apologies?** |
| Ms Raewyn Idoine | Lay (consumer/community perspectives) | 27/10/2015 | 27/10/2018 | Present |
| Dr Sarah Gunningham | Non-lay (intervention studies) | 27/10/2015 | 27/10/2018 | Present |
| Dr Nicola Swain | Non-lay (observational studies) | 27/10/2015 | 27/10/2018 | Present |
| Assc Prof Mira Harrison-Woolrych | Non-lay (intervention studies) | 27/10/2015 | 27/10/2018 | Present |
| Mrs Maliaga Erick | Lay (consumer/community perspectives) | 1/07/2015 | 1/07/2018 | Present |
| Mrs Kate O'Connor | Lay (ethical/moral reasoning) | 14/12/2015 | 14/12/2018 | Present |
| Dr Devonie Waaka | Non-Lay (intervention studies) | 13/05/2016 | 13/05/2019 | Present |

## Welcome

The Chair opened the meeting at 11:30am.

The Chair noted that it would be necessary to co-opt members of other HDECs in accordance with the Standard Operating Procedures. Mrs Kate O’Connor and Mrs Maliaga Erick confirmed their eligibility, and were co-opted by the Chair as members of the Committee for the duration of the meeting.

The Chair noted that the meeting was quorate.

The Committee noted and agreed the agenda for the meeting.

## Confirmation of previous minutes

The minutes of the meeting of 12 June 2018 were confirmed.

## New applications

|  |  |  |
| --- | --- | --- |
| **1** | **Ethics ref:** | **18/STH/142** |
|  | Title: | Short duration treatment of acute hepatitis C |
|  | Principal Investigator: | Professor Ed Gane |
|  | Sponsor: | The Kirby Institute |
|  | Clock Start Date: | 28 June 2018 |

Professor Ed Gane was not present for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study investigates if the treatment duration of sofosbuvir/velpatasvir (SOF/VEL) for hepatitis C (HCV) can be shortened when treating recently acquired infection.
2. This study will compare a treatment duration of 6 weeks against the standard time of 12 weeks.

Summary of ethical issues (resolved)

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee queried if any new safety information would be communicated to patients directly or if this would be put into addenda or new information sheets that would require ethics approval first. The researchers explained that any urgent information would be communicated directly.
2. The Committee asked what would happen in the event that the 6 weeks course of treatment is not sufficient time and if this group would receive standard care. The Researchers explained that patients would be referred on for standard care or sent to Auckland City Hospital for treatment in the event that the 6 week arm is ineffective.
3. The Committee queried if treatment would be withheld during the two year followup period. The Researchers stated that it would not.

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. Remove the requirement for withdrawing participation in writing. This can be done verbally.
2. Please include a lay explanation of what genes and genetics are in the future unspecified research information sheet. This information is currently in the main ICF so can be copied.
3. Please check that the footers do not merge into body text.
4. Please make sure that titles of sections are not orphaned on the pages beforehand.
5. Please check that paragraph spacing and justification is consistent throughout all documents
6. Please amend the ICF section on illegal activities to explain that previous illegal activities will be kept confidential but that participants should not talk about any intended activities to their doctor.

Decision

This application was *approved with non-standard conditions* by consensus.

The non-standard conditions are:

* Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).

|  |  |  |
| --- | --- | --- |
| **2** | **Ethics ref:** | **18/STH/132** |
|  | Title: | Teledermatology for scabies |
|  | Principal Investigator: | Dr Simon Thornley |
|  | Sponsor: | University of Auckland |
|  | Clock Start Date: | 28 June 2018 |

Dr Simon Thorley was present by teleconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study investigates the feasibility of using teledermatology to investigate scabies prevalence in Auckland early childhood education centres.

Summary of ethical issues (resolved)

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee noted that scabies has not been studied in New Zealand for a significant amount of time and that this study has high value.
2. The Committee asked if scabies is a symptom of health inequity or a cause of health inequity. The Researcher explained that recent research indicates that there are strong links between scabies and skin infections as well as more serious conditions.
3. The Committee suggested that, if possible, some study funding be left aside to help participants afford the cost of GP visits to seek treatment.

Summary of ethical issues (outstanding)

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee asked if the three study examinations will happen simultaneously or if these will be spaced out over the day. The Researcher stated that they would happen simultaneously. The Committee had concerns that this process might be too intense for the children and suggested the researcher investigate the possibility of parents or a chaperone from the early childhood centre attending the examination to support the child. *(Ethical Guidelines for Observational Studies para 4.2)*
2. The Committee stated that there is a strong possibility of stigma and burden for children and their families in the event that scabies is diagnosed. Please consult with the early childhood centre to understand what burdens this will place on the children, their families, and the centre. *(Ethical Guidelines for Observational Studies para 6.18)*
3. Please amend the information sheet and consent forms, taking into account the suggestions made by the committee *(Ethical Guidelines for Observational Studies para 6.10)*
4. Please provide evidence of favourable independent peer review of the study protocol (*Ethical Guidelines for Intervention Studies* Appendix 1)
5. Please justify why data will be used to track participants through the health system after study completion.

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. Please note that data must be held until ten years after participants turn sixteen.
2. Please remove the statement about interpreters unless this service will be provided.
3. Please consider a reduction in the length and complexity of the information sheet where possible.
4. Please check for wording that may imply stigmatisation e.g. “the burden of scabies”
5. The risks section must identify risks, including stigma, family cost, and privacy issues, alongside the benefits in simple lay terms.
6. Include that children may need to be excluded if they are diagnosed with scabies.

Decision

This application was *declined* by consensus, as the Committee did not consider that the study would meet the following ethical standards.

* Please amend the information sheet and consent forms, taking into account the suggestions made by the committee *(Ethical Guidelines for Observational Studies para 6.10)*
* Please address how the study will manage issues around stigma and/or disadvantage to participants as a result of their participation. *(Ethical Guidelines for Observational Studies para 4.2 & 6.10)*

|  |  |  |
| --- | --- | --- |
| **3** | **Ethics ref:** | **18/STH/134** |
|  | Title: | Frontotemporal dementia case series |
|  | Principal Investigator: | AP Maurice Curtis |
|  | Sponsor: | The University of Auckland |
|  | Clock Start Date: | 28 June 2018 |

AP Maurice Curtis was present by teleconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study is a case series that will report the clinical features of patients diagnosed with frontotemporal dementia.
2. Clinical features will include health information gathered from medical records and from interviews with related individuals.

Summary of ethical issues (resolved)

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee noted the study was of high scientific value.
2. The Committee noted that the criteria for access of identifiable data without consent under section 6.43 of the Ethical Guidelines for Observational Studies were met. They approved the access to deceased medical records as well as the records of those who would not otherwise be excluded from having their information included in the analysis due to an inability to provide informed consent.

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. Remove tickboxes
2. Please include a section that identifies the risks of participation.
3. The Committee requested the compensation wording is updated for accuracy, they suggested the following statement: *“If you were injured in this study, which is unlikely, you would be eligible* ***to apply*** *for compensation from ACC just as you would be if you were injured in an accident at work or at home. This does not mean that your claim will automatically be accepted. You will have to lodge a claim with ACC, which may take some time to assess. If your claim is accepted, you will receive funding to assist in your recovery. If you have private health or life insurance, you may wish to check with your insurer that taking part in this study won’t affect your cover.”*

Decision

This application was *approved with non-standard conditions* by consensus. The non-standard conditions are:

* Please amend the information sheet and consent forms, taking into account the suggestions made by the committee *(Ethical Guidelines for Observational Studies para 6.10)*

|  |  |  |
| --- | --- | --- |
| **4** | **Ethics ref:** | **18/STH/136** |
|  | Title: | Finding Easier Ways to See What is Happening in Your Gut? |
|  | Principal Investigator: | Professor Andrew Day |
|  | Sponsor: |  |
|  | Clock Start Date: | 28 June 2018 |

Professor Andrew Day was present in person for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study investigates a panel of non-invasive biomarkers that will enable more accurate and specific assessment of the presence of disease activity as well as resolution of intestinal damage in children with IBD compared to their healthy siblings.

Summary of ethical issues (resolved)

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee queried if tissue collected as part of the study will be retained for future unspecified research purposes. The Researchers confirmed that tissue would be destroyed as part of the study analysis.
2. The Committee noted there was sufficient justification on performing this study in children as their symptoms of IBD are different and can be more severe.

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. Please produce an ICF for adolescents who can provide full informed consent (age 16). This can be a duplication of the parental form but re-phrased so as to be addressed to the 16 year old and not parents.
2. For the information sheet for 5 – 10 year olds please consider using pictures and less written text.
3. Please add Māori cultural support contact details to the ends of all information sheets.
4. Please include a statement in the information sheet that explains to siblings that they do not have to participate in the study if they do not wish to.

Decision

This application was *approved with non-standard conditions* by consensus.

The non-standard conditions are:

* Please amend the information sheet and consent forms, taking into account the suggestions made by the committee *(Ethical Guidelines for Observational Studies para 6.10)*

|  |  |  |
| --- | --- | --- |
| **5** | **Ethics ref:** | **18/STH/137** |
|  | Title: | The GRADIENT II Study |
|  | Principal Investigator: | Dr Geoffrey Clare |
|  | Sponsor: |  |
|  | Clock Start Date: | 28 June 2018 |

Dr Geoffrey Clare was not present for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study investigates recently identified new heart hormones (peptides) and evaluates how the heart and body process them.

Summary of ethical issues (outstanding)

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. Please amend the information sheet and consent forms, taking into account the suggestions made by the committee *(Ethical Guidelines for Observational Studies para 6.10)*
2. The Committee noted that the reimbursement for human tissue seemed high and that this could be interpreted as the sale of human tissue which an activity prohibited under the Human Tissue Act 2008. Please explain that this is not the case.
3. Please clarify if there will be a questionnaire given to participants and provide this to the committee.

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. Please clarify if future unspecified research will be performed on tissue collected as part of this study. If so please provide an information sheet and consent form for this use of tissue.
2. The Committee queried the lack of a Māori tissue statement in the Participant Information Sheet. The committee recommended the following statement: “*You may hold beliefs about a sacred and shared value of all or any tissue samples removed. The cultural issues associated with sending your samples overseas and/or storing your tissue should be discussed with your family/whanau as appropriate. There are a range of views held by Māori around these issues; some iwi disagree with storage of samples citing whakapapa and advise their people to consult prior to participation in research where this occurs. However, it is acknowledged that individuals have the right to choose.”*
3. Please rephrase the statement about probing in the ECG explanation as this is inappropriate.
4. Please clarify if reasonable travel expenses will be reimbursed (e.g. parking) and include this in the icf.
5. Please explain the need for the extra punch biopsy.

Decision

This application was *provisionally approved* by consensus, subject to the following information being received.

* Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).
* Please explain the extra procedures mentioned in the protocol (*Ethical Guidelines for Intervention Studies* *para 5.41*)
* Please confirm that the study does not involve the sale of Human Tissue. *(Human Tissue Act 2008)*

This following information will be reviewed, and a final decision made on the application, by Dr Devonie Waaka and Mrs Raewyn Idoine.

|  |  |  |
| --- | --- | --- |
| **6** | **Ethics ref:** | **18/STH/138** |
|  | Title: | Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD. |
|  | Principal Investigator: | Dr Leanne Berkahn |
|  | Sponsor: | Australasian Leukaemia and Lymphoma Group |
|  | Clock Start Date: | 28 June 2018 |

Dr Leanne Berkahn and Ms Fadiya Al-Abuwsi were present by teleconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study investigates if a new chemotherapy regimen BrECADD (Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Dacarbazine, Dexamethasone), is non-inferior to BEACOPP (Doxorubicin, Etoposide, Procarbazine, Prednisone, Vincristine, Bleomycin) as first line treatment in advanced stage classical Hodgkin lymphoma

Summary of ethical issues (resolved)

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee suggested a study participant card be provided to participants.
2. The Committee confirmed that there is no future unspecified research on tissue as part of this study.
3. The Committee noted that participants have a right to receive a result of the research under the HDC Code of Patient Rights right 6.3.d.

Summary of ethical issues (outstanding)

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. Please localise the information sheet including changing references to refer to New Zealand legislation, ethics committees, complaints details, and remove references to items that are irrelevant in a New Zealand context e.g. a pharmacy dispensing fee.
2. Remove yes/no tickboxes for items where ticking no would exclude someone from participation.
3. Please break up the text into smaller paragraphs to improve readability.
4. Please make sure that sub-headings are not orphaned at the bottom of pages with the rest of the text following on the next.
5. Please provide a lay-friendly title for the icf
6. Please explain the reason that tissue samples must be sent overseas and where these will be going.
7. Remove the opt-out option from the consent form as HDECs do not approve opt-out consent. This item is essential to study participation but participants will be free to withdraw their sample at any time.
8. Please use the HDEC contraception wording which can be found on the HDEC website.
9. Please explain side effects in lay language and not just in medical terms.
10. Remove the Catholic wording from the ICF.

Decision

This application was *provisionally approved* by consensus, subject to the following information being received.

* Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).

This following information will be reviewed, and a final decision made on the application, by Mrs Sarah Gunningham and Ms Raewyn Idoine.

|  |  |  |
| --- | --- | --- |
| **7** | **Ethics ref:** | **18/STH/139** |
|  | Title: | Pre-emptive analgesic and anti-inflammatory effects of etoricoxib and sustained-release ibuprofen following impacted mandibular third molar surgery. |
|  | Principal Investigator: | Ms Yen Je (Jessica) Lee |
|  | Sponsor: | University of Otago |
|  | Clock Start Date: | 28 June 2018 |

Ms Yen Je (Jessica) Lee was not present for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study investigates the pre-emptive analgesic and anti-inflammatory effects of etoricoxib and sustained-release ibuprofen following impacted mandibular third molar surgery.

Summary of ethical issues (outstanding)

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).
2. Please clearly outline the recruitment process in the study protocol including who will make the approach and when this is likely to occur. (*Ethical Guidelines for Intervention Studies* *para 5.41*)
3. Please clarify if renal function will be checked and when this will happen. (*Ethical Guidelines for Intervention Studies* *para 5.41*)

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. Add the risks and side effects of the medicines used in the study to the information sheet. E.g. GI bleeding.
2. Please add footers and page numbers for readability
3. Please clarify that the “2 day’s appointment” mentioned on page two will not be for two day’s duration.
4. Please remove yes/no tick boxes for all items that are not truly optional.
5. Please include the doses of the study medicines in the information sheet.
6. Please amend the confidentiality section for accuracy i.e. study data will be retained in a de-identified format.
7. Please seek consent for informing participant’s GPs of their participation
8. Please include that combining two types of NSAIDs could increase the risk of bleeding.
9. Please explain the exclusion criteria in lay terms.
10. Please add the contact details for the HDC’s advocacy service to the back of the information sheet. These can be found on the HDECs information sheet template.

Decision

This application was *provisionally approved* by consensus, subject to the following information being received.

* Please amend the study protocol taking into account the suggestions made by the Committee. (*Ethical Guidelines for Intervention Studies* *para 5.41*)
* Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).

This following information will be reviewed, and a final decision made on the application, by Dr Nicola Swain and Ms Raewyn Idoine.

|  |  |  |
| --- | --- | --- |
| **8** | **Ethics ref:** | **18/STH/140** **(CLOSED)** |
|  | Title: | MK-7264-034 Phase 2a in Women with Endometriosis-related Pain |
|  | Principal Investigator: | Dr Simon Carson |
|  | Sponsor: | MSD |
|  | Clock Start Date: | 28 June 2018 |

Kim Huljich was present by teleconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Decision

This application was *provisionally approved* by consensus.

|  |  |  |
| --- | --- | --- |
| **9** | **Ethics ref:** | **18/STH/141 (CLOSED)** |
|  | Title: | A Single Dose PK-PD study of R-107 in Patients with Specific Phobia (spider phobia) |
|  | Principal Investigator: | Dr Paul W Glue |
|  | Sponsor: | Douglas Pharmaceuticals Ltd |
|  | Clock Start Date: | 28 June 2018 |

Dr Paul W Glue was present by teleconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Decision

This application was *provisionally approved* by consensus.

|  |  |  |
| --- | --- | --- |
| **10** | **Ethics ref:** | **18/STH/129** |
|  | Title: | Efficacy of warm humidified insufflation for reducing post-operative ileus. |
|  | Principal Investigator: | Dr Cecile Bergzoll |
|  | Sponsor: | Fisher and Paykel Healthcare |
|  | Clock Start Date: | 28 June 2018 |

Ms Jess Fogarin was present by teleconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study investigates the efficacy of warm humidified insufflation for reducing post-operative ileus in women undergoing open surgery for presumed advanced ovarian, tubal or peritoneal malignancy.

Summary of ethical issues (outstanding)

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).
2. The Committee stated that a research nurse may not be the best person to make the initial research recruitment approach and suggested that a more informed member of staff do this. Please amend the study protocol taking into account the suggestions made by the Committee. Please also amend the study protocol to provide a clear outline of the consenting process including who will be making the approach and when. (*Ethical Guidelines for Intervention Studies* *para 5.41*)

The Committee requested the following changes to the Participant Information Sheet and Consent Form:

1. The Committee queried the lack of a Māori tissue statement in the Participant Information Sheet. The committee recommended the following statement: “*You may hold beliefs about a sacred and shared value of all or any tissue samples removed. The cultural issues associated with sending your samples overseas and/or storing your tissue should be discussed with your family/whanau as appropriate. There are a range of views held by Māori around these issues; some iwi disagree with storage of samples citing whakapapa and advise their people to consult prior to participation in research where this occurs. However, it is acknowledged that individuals have the right to choose.”*
2. Please better communicate the risks and process of performing the punch biopsies. For example how long this process will take.
3. The Committee noted that, in general, the information sheet presents information in a way that is not lay-friendly. The Committee recommended the sheet be re-written in a way that is more lay-friendly and less catered towards a clinical audience. For example, the first sentence is not lay friendly.
4. Please re-write the “what will my participation involve” section as this does not adequately describe study procedures.
5. The Committee queried the lack of a Māori tissue statement in the Participant Information Sheet. The committee recommended the following statement: “*You may hold beliefs about a sacred and shared value of all or any tissue samples removed. The cultural issues associated with sending your samples overseas and/or storing your tissue should be discussed with your family/whanau as appropriate. There are a range of views held by Māori around these issues; some iwi disagree with storage of samples citing whakapapa and advise their people to consult prior to participation in research where this occurs. However, it is acknowledged that individuals have the right to choose.”*
6. Please provide contact details for the coordinating investigator, Māori cultural support details, and the details of the HDC’s advocacy support service to the end of the information sheet.
7. Please clarify that the PCR test will destroy any tissue collected as part of the study.
8. Please re-write the explanation of the device that begins “Gas will be slowly blown” for readability and clarity.
9. Please explain that there are risks associated with the procedure and what these are, as well as there may be no benefits from participation.
10. Please explain that Fisher and Paykel Healthcare are paying for the device in the study.

Decision

This application was *provisionally approved* by consensus, subject to the following information being received.

* Please amend the study protocol taking into account the suggestions made by the Committee. (*Ethical Guidelines for Intervention Studies* *para 5.41*)
* Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (*Ethical Guidelines for Intervention Studies* *para 6.22*).

This following information will be reviewed, and a final decision made on the application, by A/Prof Mira Harrison-Woolrych and Ms Raewyn Idoine.

## Substantial amendments

|  |  |  |
| --- | --- | --- |
| **1** | **Ethics ref:** | **17/STH/112/AM03** |
|  | Title: | (duplicate) He Korowai Manaaki: Wairoa |
|  | Principal Investigator: | Associate Professor Beverley Lawton |
|  | Sponsor: | Associate Professor Beverley Lawton |
|  | Clock Start Date: | 29 May 2018 |

Associate Professor Beverley Lawton was present by teleconference for discussion of this amendment.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of ethical issues (resolved)

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee were satisfied with the researcher’s attempts to protect participant confidentiality whilst working around practical issues associated with the use of data.

Decision

This application was *approved* by consensus.

## General business

1. The Committee noted the content of the “noting section” of the agenda.
2. The Chair reminded the Committee of the date and time of its next scheduled meeting, namely:

|  |  |
| --- | --- |
| **Meeting date:** | 14 August 2018, 11.30 AM |
| **Meeting venue:** | Sudima Hotel, Christchurch Airport, 550 Memorial Drive, Christchurch |

1. **Problem with Last Minutes**

The minutes of the previous meeting were agreed and signed by the Chair and Co-ordinator as a true record.

The meeting closed at 5:00pm.